Mperia Therapeutics Overview

  • Founded
  • 2016
Founded
  • Status
  • Private
  • Latest Deal Type
  • Seed
  • Latest Deal Amount
  • $771K
Latest Deal Amount
  • Investors
  • 1

Mperia Therapeutics General Information

Description

Provider of CD36-based novel immunotherapies designed to target and treat macrophage-driven inflammation. The company's immunotherapies deal with dry age-related macular degeneration, atherosclerosis and non-alcoholic steatohepatitis through low molecular weight peptides which act as immunomodulators of inflammation, providing patients with anti-inflammatory therapies.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Drug Discovery
Primary Office
  • 4 Westmount Square
  • Suite 160
  • Montreal, Quebec H3Z 2S6
  • Canada
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Mperia Therapeutics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
1. Seed Round 12-Sep-2016 $771K 00000 Completed Startup
To view Mperia Therapeutics’s complete valuation and funding history, request access »

Mperia Therapeutics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Provider of CD36-based novel immunotherapies designed to target and treat macrophage-driven inflammation. The company's
Biotechnology
Montreal, Canada
00000
000000000 00000

00000000

uis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000000000000
Windsor, United Kingdom
0000
00.00 0000-00-00
0000000000 0 0000

00000000

quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure
0000000000000
Toronto, Canada
000000000000
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mperia Therapeutics Competitors (3)

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Macrophage Pharma Venture Capital-Backed Windsor, United Kingdom 0000 0000000000 0 0000
0000000000 0000000 Accelerator/Incubator Backed Toronto, Canada 000000000000
0000000000 0000000 Corporation Dublin, OH
To view Mperia Therapeutics’s complete competitors history, request access »

Mperia Therapeutics Executive Team (2)

Name Title Board Seat Contact Info
Véronique Bougie Chief Executive Officer & Chief Operating Officer
Huy Ong Ph.D Co-Founder & Chief Scientific Officer
To view Mperia Therapeutics’s complete executive team members history, request access »

Mperia Therapeutics Board Members (4)

Name Representing Role Since
Élizabeth Douville Ph.D GeneChem Board Observer 000 0000
Jean-Christophe Leroux Ph.D Self Chairman of Clinical Advisory Board 000 0000
Kevin McBride Ph.D GeneChem Board Member 000 0000
To view Mperia Therapeutics’s complete board members history, request access »

Mperia Therapeutics Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
GeneChem Venture Capital Minority 000 0000 000000 0
To view Mperia Therapeutics’s complete investors history, request access »